Pot Prices: July 2017 THMQ

By
Mike Hughes

Market Analysis: All indices, with the exception of the Southern Index, finished July above their previous month’s average. The US Price Index jumped $12 from its June average to reach its highest average of the year so far ($347). After reaching a year-high average in June, the Southern Index fell to $366 per ounce, just $3 above its YTD average.

Current US Price Index: $347 (last month: $335, Year-to-Date: $331)
Current Eastern Price Index: $358 (last month: $357, YTD: $352)
Current Southern Price Index: $366 (last month: $370, YTD: $363)
Current Western Price Index: $265 (last month: $256, YTD: $267)

The top five strains (with average price) were: Kush ($345), Diesel ($352), Girl Scout Cookies ($368), Blue Dream ($320) and Haze ($337).

QUOTES:

(Querkle) “The black market still dominates around here.” –Ridgway, CO

(Cheese) “This stuff stinks up my whole damn house!” –Nashville, TN

(Blackberry Kush) “We are still battling bad science, corrupt politicians, big pharma…” –Sydney, Australia

(Gorilla Glue #4) “Beautiful, dense, sticky, stinky nugs.” –New York, NY

Mike Hughes

By
Mike Hughes

Recent Posts

DEA Moves To Reclassify Cannabis Under Schedule III in Historic Move, Report Indicates

The DEA under the Biden administration finally proposed the process of moving cannabis to Schedule…

5 hours ago

Psychedelic Drug Market Poised to Hit $4.6B by 2030

MarketDigits released predictions about the psychedelic drug sector showing ample growth.

14 hours ago

Chronic Pot Use Has Minimal Effect on Motivation, Study Shows

The debunking of the "lazy stoner" stereotype isn't breaking news, but sometimes it's nice to…

14 hours ago

Kansas Medical Cannabis Proposal Dead for 2024

A bill to legalize medical marijuana in Kansas won’t become law this year after a…

14 hours ago

Santa Barbara County Approves Study To Address Ongoing Cannabis Odor

There are 116 acres of land in unincorporated Santa Barbara that are being used for…

14 hours ago

Psychedelic Research Proves Rather Tricky for the FDA

Nasty claims of bias and impartial research stand in the way of MDMA gaining FDA…

14 hours ago